Ao minuto: "Uma civilização inteira morrerá esta noite", ameaça Trump. Casa Branca nega planos para uso de armas nucleares no Irão

[Luka!]

This could mean that part of the market sould be replaced by the new technology !! (ENTRY OPPORTUNITY)

Quote:

Sector Snap: Computer-aided mammography


Shares of computer-aided mammography screening devices fell Thursday on the heels of a report suggesting that the technology doesn't improve the odds of cancer detection.

On Thursday, the New England Journal of Medicine published a study of the screening technology looking at 43 facilities in the states of Washington, Colorado and New Hampshire from 1998 through 2002. The study concluded that the technology did not significantly improve the cancer-detection rate of invasive breast cancer.

Shares of Hologic Inc. and iCAD Inc., companies that specialize in the technology, dropped on the report. Hologic shares fell $2.02, or 3.3 percent, to $59.15 in midday trading on the Nasdaq Stock Market at above-average volume. Shares of iCAD, which have ranged between $1.28 and $5.06 over the past 52 weeks, dropped 52 cents, or 14.4 percent, to $3.11 on the Nasdaq at nearly six times average volume.

Even large companies with a presence in the sector felt pressure. Shares of Eastman Kodak Co. slipped 4 cents to $23.42, and General Electric Co. shares fell 11 cents to $35. Both trade on the New York Stock Exchange.



However, WR Hambrecht analyst Emily Johnson dismissed the study, calling it poorly designed and using outdated equipment. She recommended that investors buy shares on the weakness.

Johnson said the detection technology has been upgraded considerably since the study. The analyst added the study did not include detection of breast cancer in its early stages, where the technology is most effective, and that the average time the centers had been using the technology was seven months, when the learning curve ranges from six to nine months.

"This study not expected to impact purchasing decisions at all," Johnson told investors. "We have had the opportunity to speak to a handful of radiologists and all indicated that this study was flawed and would not deter them from purchasing CAD going forward ."